Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02901587 · ClinicalTrials.gov registry record · Phase 1
Study Investigating the Effect of Lu AF35700 on Cardiac Repolarization in Men and Women With Schizophrenia and Schizoaffective Disorder
A Phase 1 study of Schizophrenia and Schizoaffective Disorder, sponsored by H. Lundbeck A/S.
- Completed
- Registry status
- Phase 1
- Development phase
- 119
- Enrollment target
- 1
- Study location
NCT02901587: Completed Phase 1 study of Schizophrenia and Schizoaffective Disorder, sponsored by H. Lundbeck A/S.
NCT02901587 is a Phase 1 study of Schizophrenia and Schizoaffective Disorder that has completed, run by H. Lundbeck A/S. The registered enrollment target is 119 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (46% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02901587, a Phase 1 study of Schizophrenia and Schizoaffective Disorder, has completed, sponsored by H. Lundbeck A/S.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 119 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to investigate the effect of Lu AF35700 on electrical activity in the heart as measured on an electrocardiogram (ECG) in patients with schizophrenia or schizoaffective disorder after 6 weeks of treatment
Conditions Studied
Interventions
- DRUG Lu AF35700 (10 mg/day)
- DRUG Lu AF35700 (30 mg/day)
- DRUG Quetiapine (Seroquel XR® 800 mg/day)
Study Locations (1)
California
- US1104 - Long Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 119 participants |
| Start Date | 2016-09 |
| Est. Completion | 2018-04-18 |
| Phase | Phase 1 |
What the finished NCT02901587 record still lists
NCT02901587 is an interventional study that assigns participants to a tested intervention. The registered 119 participants enrollment target is mid-sized for trials with a published cap, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (46% lower).
The record links to 2 conditions, with Schizophrenia appearing as the primary indexed condition, and to 3 interventions - of which Lu AF35700 (10 mg/day) is the first listed.
NCT02901587 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT02901587 about?
NCT02901587 is a clinical study titled "Study Investigating the Effect of Lu AF35700 on Cardiac Repolarization in Men and Women With Schizophrenia and Schizoaffective Disorder". The purpose of this study is to investigate the effect of Lu AF35700 on electrical activity in the heart as measured on an electrocardiogram (ECG) in patients with schizophrenia or schizoaffective disorder after 6 weeks of treatment
What is the current status of trial NCT02901587?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 119 participants. The study started on 2016-09. Estimated completion is 2018-04-18.
What conditions does trial NCT02901587 study?
This clinical trial studies the following conditions: Schizophrenia, Schizoaffective Disorder.
What interventions are being tested in trial NCT02901587?
The interventions under investigation include: Lu AF35700 (10 mg/day) (DRUG), Lu AF35700 (30 mg/day) (DRUG), Quetiapine (Seroquel XR® 800 mg/day) (DRUG).
Who is sponsoring clinical trial NCT02901587?
This trial is sponsored by H. Lundbeck A/S, which has 72 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02901587 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02901587's enrollment target sits among peer trials
119 127th of 315 higher than 189 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Tolerability of MDMA in Schizophrenia
RECRUITING · Phase 1
-
Imaging Synapses With [11C] UCB-J in the Human Brain
RECRUITING · Phase 1
-
A Study to Evaluate the Dose Levels, Safety, and Drug Levels of Single KarXT Intramuscular Injection in Participants With Schizophrenia
RECRUITING · Phase 1
-
Proposal To Develop A Rapid And Cost-Effective Diagnostic Test For Schizophrenia
RECRUITING · Phase 1
-
Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
RECRUITING · Phase 1
-
Genetics of Cannabis Use Disorder and Cannabinoid Response in Humans
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04870762 · 119 participants · Phase 2
Customized 3D Printed Oral Stents During Head and Neck Radiotherapy
- NCT05559853 · 119 participants
Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment
- NCT06564389 · 119 participants · Phase 1
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
- NCT06742801 · 119 participants · NA
Onyx™ Liquid Embolic IDE Clinical Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia